- Short Report
- Open Access
Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein
BMC Research Notes volume 6, Article number: 445 (2013)
The ATP-binding cassette (ABC) transporters P-glycoprotein (P-gp)/ABCB1 and breast cancer resistance protein (BCRP)/ABCG2 are involved in the intestinal absorption and renal excretion of various substrate drugs. Their activities affect sub-therapeutic drug concentrations and excretion of natural transporter substrates. The new oral anti-HCV drug telaprevir has dramatically improved the efficacy of hepatitis-C virus (HCV) treatment, and recent studies have suggested a possible pharmacological interaction between telaprevir and P-gp. We studied the kinetics of in vitro interactions between telaprevir and P-gp and BCRP to understand the molecular basis of that interaction.
The effect of telaprevir on P-gp- and BCRP-mediated transport was evaluated by an in vitro vesicle transporter assay using different transport substrates, and the kinetics of transporter inhibition was determined. The results showed that telaprevir could inhibit P-gp- and BCRP-mediated transport in the in vitro vesicle transport assay, with each IC50 values of ≈ 7 μmol/L and ≈ 30 μmol/L, respectively. Analyses of Lineweaver–Burk plots showed that telaprevir was likely to be a competitive inhibitor against P-gp and BCRP. Photoaffinity labeling experiments were employed to observe competitive inhibition by telaprevir using iodoarylazidoprazosin (IAAP) as a binding substrate for P-gp and BCRP. These experiments revealed that telaprevir inhibited [125I]-IAAP-binding with P-gp and BCRP.
Telaprevir competitively inhibited P-gp and BCRP, and P-gp-mediated transport was more sensitive to telaprevir compared with BCRP-mediated transport. These data suggest that telaprevir represses the transporter functions of P-gp and BCRP via direct inhibition.
Telaprevir is a new, orally-administered drug acting directly against hepatitis-C virus (HCV) non-structural 3/4A (NS3/4A) protease . Combination of telaprevir, pegylated interferon and ribavirin has been shown to increase significantly the sustained virological response in patients . Antiviral chemotherapies for the HCV, hepatitis-B virus (HBV) and human immunodeficiency virus (HIV) comprise various drug combinations, so pharmacological drug–drug interactions with members of the cytochrome P-450 superfamily have been considered carefully . With regard to drug interactions with transporters, functional interactions between anti-HCV drugs and the ABC transporter protein have become apparent [4, 5]. Telaprevir is reported to be a substrate and an inhibitor of P-gp, but not of breast cancer resistance protein (BCRP)  (available at http://pi.vrtx.com/files/uspi_telaprevir.pdf; 2011); however, the biochemical basis of such differences in inhibition is incompletely understood. Moreover, understanding based on observations from clinical and cell-based assays should include direct and indirect effects by metabolic enzymes [7–9]. Therefore, studies on the direct effects between drugs and transporters are necessary to understand the mechanism of complicated drug–drug interactions.
We have been studying various drug interactions with P-gp and BCRP [10–16]. For example, verapamil and tyrosine kinase inhibitors (TKIs) such as imatinib, gefitinib, and erlotinib could be inhibitors of P-gp. Fumitremorgin C (FTC), certain flavonoids and the TKIs mentioned above also inhibit BCRP-mediated transport. Our studies have suggested that multiple binding sites on ABC transporter proteins cause complicated differences in transporter inhibition, depending on the substrate and inhibitor [15, 17, 18].
In the present study, we investigated the biochemical basis of the in vitro interactions of P-gp and BCRP with telaprevir. We analyzed their kinetics using in vitro cell-free systems to provide mechanistic insights into the interaction between ABC transporters and telaprevir.
Telaprevir was purchased from Selleck Chemicals (Houston, TX, USA). FTC was from Alexis (San Diego, CA, USA) and verapamil was from Sigma–Aldrich (St. Louis, MO, USA). [3H]-labeled vincristine (VCR), estrone 3-sulfate (E1S), methotrexate (MTX), and [125I]-labeled iodoarylazidoprazosin (IAAP) were purchased from Perkin-Elmer Life Sciences (Boston, MA, USA). All other reagents were available commercially.
Intravesicular transport assay
Plasma membrane vesicles (22.5 μg of protein) were prepared from K562/MDR and K562/BCRP cells as described previously . Then, they were mixed with [3H]-labeled VCR (for P-gp) or E1S or MTX (for BCRP), and telaprevir at the indicated concentration in the reaction buffer (0.25 mol/L sucrose, 10 mmol/L HEPES-NaOH (pH 7.4), 10 mmol/L MgCl2, 10 mmol/L phosphocreatine, 100 μg/mL creatine phosphokinase, with or without 3 mmol/L adenosine triphosphate (ATP)) in a total volume of 50 μL. After 10 min of incubation at 25°C, the reaction mixture was stopped by the addition of ice-cold stop solution (0.25 mol/L sucrose, 10 mmol/L HEPES-NaOH (pH 7.4), 0.1 mol/L NaCl) and centrifuged at 18,000 × g for 10 min at 4°C. The pellets were solubilized by a liquid scintillation counter to measure their radioactivity levels. For kinetics analyses, the Michaelis–Menten equation and Lineweaver–Burk plots were applied to visualize the mechanism of transport inhibition, as v = Vmax[S]/([S] + (1 + [I]/Ki)Km), where [S] and [I] are concentrations of substrate and inhibitor respectively, and v is velocity of substrate uptake by transporter. The enzymatic values for Michaelis–Menten constants of substrates (Km) and inhibitors (Ki) and the maximum uptake rate for a transporter-mediated process (Vmax) were calculated by estimating the slopes (=Km(1 + [I]/Ki)/Vmax), x-intercepts (= - 1/(Km(1 + [I]/Ki)) and y-intercepts (=1/Vmax) on the plots mentioned above in competitive-inhibition mode. Competitive inhibition causes different slopes and x-intercepts between the two data, but with similar y-intercepts. Non-competitive inhibition shows a similar x-intercept but different slopes and y-intercepts. Uncompetitive inhibition shows similar slopes.
Photoaffinity labeling with IAAP
Photoaffinity labeling assay was done as described previously . In brief, plasma membrane fractions (45 μg protein/sample) were pre-incubated at 4°C for 5 min at the indicated concentration of telaprevir in 0.25 mol/L sucrose solution containing 10 mmol/L HEPES-NaOH (pH 7.4). Then, 5 nmol/L radioactive iodine-labeled IAAP, i.e., [125I]-IAAP (2200 Ci/mmol), was added and the mixture incubated for an additional 10 min. Samples were kept on ice and illuminated with an ultraviolet lamp (B-100AP; UVP, Upland, CA, USA) at 365 nm for 30 min. These processes were carried out on ice. For the BCRP assay, the labeled BCRP protein was solubilized in a buffer (1% NP-40, 20 mmol/L Tris–HCl (pH 7.4), 150 mmol/L NaCl, 1 mmol/L ethylenediamine tetra-acetic acid (EDTA)) and immunoprecipitated with anti-BCRP antibody BXP-21 (Millipore, Billerica, MA, USA), then solubilized by Laemmli sodium dodecyl sulfate (SDS) buffer. For the P-gp assay, membrane fractions were solubilized directly by Laemmli SDS buffer. Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and gels were dried. The binding of [125I]-IAAP with P-gp and BCRP was quantified using a FLA7000 Bioimage Analyzer (Fuji Film, Tokyo, Japan) and Multi-Gauge software (Fuji Film).
Inhibition of P-gp and BCRP by telaprevir in vitro
The intravesicular transport assay was carried out to analyze the kinetics of telaprevir inhibition on P-gp- and BCRP-mediated transport in vitro.
Figure 1A shows that telaprevir inhibited ATP-dependent [3H]-VCR transport in vitro in a dose-dependent manner. Analyses of Lineweaver–Burk plots showed that the inhibitory mode of telaprevir for P-gp-mediated VCR transport was competitive (Figure 1B). The calculated Vmax values (pmol/mg/10 min) were 8.2 in the control condition and 7.1 in the presence of telaprevir (20 μmol/L). The calculated Ki value of telaprevir on P-gp-mediated VCR transport was 4.8 μmol/L (Table 1). These results suggested that telaprevir acted as a competitive inhibitor for P-gp-mediated VCR transport.
Inhibitory effect of telaprevir on BCRP-mediated transport in vitro was also analyzed using two transport substrates: E1S and MTX. Telaprevir inhibited [3H]-E1S and [3H]-MTX transport in a dose-dependent manner at comparable levels (Figure 2A). Analyses of Lineweaver–Burk plots showed that the inhibitory mode of telaprevir for BCRP-mediated E1S and MTX transports appeared to be competitive (Figure 2B). The calculated Vmax values (pmol/mg/10 min) were 38 in the control condition and 41 in the presence of telaprevir (50 μmol/L). Similar analysis on BCRP-mediated MTX transport also demonstrated that the calculated Vmax values (pmol/mg/10 min) were 4.9 in the control condition and 4.6 in the presence of telaprevir (50 μmol/L). The calculated Ki value of telaprevir on BCRP-mediated E1S transport was 44 μmol/L, and that on BCRP-mediated MTX transport was 94.8 μmol/L; these findings suggested that BCRP was more resistant to telaprevir than P-gp (Table 2).
The calculated half-maximal inhibitory concentration (IC50) values of telaprevir for each substrate transport are summarized in Table 3. The values suggested that a higher concentration (≈30 μmol/L) of telaprevir was required to elicit 50% inhibition of BCRP-mediated transport compared with that of P-gp-mediated transport (7 μmol/L). These results suggested that the inhibitory kinetics of telaprevir on the transporter function of BCRP and P-gp were likely to be competitive.
Effects of telaprevir on IAAP-binding to P-gp and BCRP
The data mentioned above could not be used to ascertain if telaprevir competed with substrate binding on the transporters. Thus, we examined the effect of telaprevir on [125I]-IAAP-binding with P-gp and BCRP by a photoaffinity labeling experiment to observe the direct competition of telaprevir with the transporter substrate IAAP. Telaprevir apparently suppressed [125I]-IAAP-binding with P-gp in a dose-dependent manner (Figures 3A and B). In contrast, [125I]-IAAP-binding with BCRP was relatively resistant to telaprevir than that with P-gp, and a higher concentration of telaprevir was required for the inhibition of IAAP-binding with BCRP. The calculated IC50 values were ≈ 17 μmol/L for P-gp and >80 μmol/L for BCRP (Table 4). Overall, our results revealed that telaprevir would be a direct competitive inhibitor for P-gp and BCRP, and that P-gp would be a better target for telaprevir than BCRP.
Telaprevir has been reported to be a substrate and inhibitor of P-gp . Recent clinical pharmacokinetic and pharmacodynamic studies suggested enhanced absorption of digoxin by inhibition or saturation of P-gp in the intestine due to telaprevir in the gut [7, 8]. Such studies suggested that telaprevir is a substrate and inhibitor of CYP 3A4 and P-gp in vivo. However, biochemical analyses are needed to clarify the mechanism of biochemical interaction between telaprevir and P-gp.
Our previous studies on ABC transporters revealed that verapamil and TKIs (including imatinib, gefitinib, erlotinib and sunitinib) are inhibitors of P-gp as competitive inhibitors [13–15]. In addition, we showed that FTC, certain flavonoids and the TKIs mentioned above are potential competitive inhibitors of BCRP . In the present study, we demonstrated that telaprevir is a potential direct inhibitor of P-gp and BCRP. Moreover, to provide mechanistic insights for understanding the interaction between ABC transporters and telaprevir, our analyses of photoaffinity labeling and kinetics showed, for the first time, that telaprevir could be a direct competitive inhibitor for P-gp and BCRP. In vitro cell-free experiments showed that the IC50 value of telaprevir-mediated P-gp inhibition was as low as 7 μmol/L. This concentration would be reached in the gut after oral administration of telaprevir. In contrast, BCRP-mediated transport was relatively insensitive to telaprevir, and a higher concentration of telaprevir was required for inhibition of IAAP-binding with BCRP. The HCV protease inhibitor boceprevir has also been reported to interact with P-gp and BCRP using a cellular system [9, 19]. However, the inhibitory effect of boceprevir on P-gp seemed to be very low, and that on BCRP was shown to be weak (IC50 ≈ 80 μM) in that study. Combined with the data in the present study, telaprevir appears to be a strong inhibitor of P-gp, and we hypothesize that intestinal P-gp would be a pharmacological target for telaprevir.
Similar inhibitory potential of telaprevir on other transporters has been characterized (albeit examined by experimental cellular systems). This characterization has been mainly on the renal transporters OCT2 and MATE1 with IC50 values (μmol/L) of 6.4 and 23.0, and hepatic transporters OATP1B1, OATP1B and OCT1, with IC50 values of 2.2, 36.8 and 20.7, respectively . However, the renal clearance of digoxin (a P-gp substrate) has been reported to be similar to that without telaprevir . Hence, the effect of telaprevir on P-gp activity in the kidney seems to be minimal. We suspect that the steady-state concentration of telaprevir in each tissue may be an important factor modulating the activities of P-gp and other transporters.
Our data revealed that telaprevir-mediated P-gp inhibition would be mediated by a direct competitive mechanism. Hence, the combination of substrate and inhibitor could make prediction of drug–drug interactions on P-gp in each setting more difficult. Indeed, many patients suffering from HCV and HIV might be subjected to anti-HIV drugs and anti-HCV drugs, and many of those antiviral drugs are known to interact with CYPs and transporter proteins. Multiple binding sites are suggested on ABC transporter proteins , so a complicated drug combination could cause complex drug–drug interactions by complicated transporter inhibition mechanism. Thus, detailed analyses for each drug based on cell-free systems could contribute to better understanding of the mechanisms of drug–transporter interactions, particularly those in combination chemotherapy.
Telaprevir can inhibit P-gp- and BCRP-mediated transport, and P-gp-mediated transport is more sensitive to telaprevir-mediated inhibition. Our study will be helpful for theoretical consideration of interactions between intestinal P-gp and telaprevir during long-term anti-HCV chemotherapy.
Breast cancer resistance protein
50% inhibitory concentration.
Kwong AD, Kauffman RS, Hurter P, Mueller P: Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol. 2011, 29: 993-1003. 10.1038/nbt.2020.
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R: et al., Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011, 364: 2405-2416. 10.1056/NEJMoa1012912.
Seden K, Back D: Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS. 2011, 6: 514-526. 10.1097/COH.0b013e32834b54dc.
Kis O, Robillard K, Chan GN, Bendayan R: The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci. 2010, 31: 22-35. 10.1016/j.tips.2009.10.001.
Muller F, Fromm MF: Transporter-mediated drug-drug interactions. Pharmacogenomics. 2011, 12: 1017-1037. 10.2217/pgs.11.44.
Garg V, Kauffman RS, Beaumont M, van Heeswijk RP: Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012, 17: 1211-1221. 10.3851/IMP2356.
Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RP: Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol. 2012, 52: 1566-1573. 10.1177/0091270011419850.
Kunze A, Huwyler J, Camenisch G, Gutmann H: Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012, 84: 1096-1102. 10.1016/j.bcp.2012.07.032.
Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM: et al., In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos. 2013, 41: 668-681. 10.1124/dmd.112.049668.
Imai Y, Tsukahara S, Asada S, Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004, 64: 4346-4352. 10.1158/0008-5472.CAN-04-0078.
Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y: Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther. 2004, 3: 1119-1125.
Katayama K, Masuyama K, Yoshioka S, Hasegawa H, Mitsuhashi J, Sugimoto Y: Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother Pharmacol. 2007, 60: 789-797. 10.1007/s00280-007-0426-7.
Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y: Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291 T > C) of BCRP/ABCG2 gene. Cancer Sci. 2010, 101: 1493-1500. 10.1111/j.1349-7006.2010.01539.x.
Katayama K, Shibata K, Mitsuhashi J, Noguchi K, Sugimoto Y: Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling. Anticancer Res. 2009, 29: 1059-1065.
Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009, 100: 1701-1707. 10.1111/j.1349-7006.2009.01213.x.
Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y: Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009, 61: 26-33. 10.1016/j.addr.2008.07.003.
Giri N, Agarwal S, Shaik N, Pan G, Chen Y, Elmquist WF: Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos. 2009, 37: 560-570. 10.1124/dmd.108.022046.
Wise JG: Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry. 2012, 51: 5125-5141. 10.1021/bi300299z.
Kiser JJ, Burton JR, Anderson PL, Everson GT: Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012, 55: 1620-1628. 10.1002/hep.25653.
This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, from the Ministry of Health, Labour and Welfare, Japan, and from Nateglinide Memorial Toyoshima Research and Education Fund.
The authors declare that they have no competing interests.
YF, KN, TS and KK carried out experiments and data analyses. KN and YS designed the study and supervised the data. YF, KN and YS wrote the manuscript. All authors approved the final manuscript.
About this article
Cite this article
Fujita, Y., Noguchi, K., Suzuki, T. et al. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein. BMC Res Notes 6, 445 (2013) doi:10.1186/1756-0500-6-445
- Breast cancer resistance protein
- Vesicle transporter assay
- Photoaffinity labeling